Autoimmune Hemolytic Anemia Treatment Industry Revenue to Reach $1.95 Billion by 2029 with CAGR of 8.6% (2025–2029)
Claim 20% Off With Code ONLINE20 – Explore Market Reports Covering Trade Trends, Regulatory Changes, and Growth Insights
What Is the Current Market Size and Growth Rate of the Autoimmune Hemolytic Anemia Treatment Market?
The autoimmune hemolytic anemia treatment market size has grown strongly in recent years. It will grow from $1.3 billion in 2024 to $1.4 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to increasing disease awareness among healthcare providers, rising incidence of autoimmune disorders, growth in hospital infrastructure, growing number of published clinical studies, and rising incidence of infections.
The autoimmune hemolytic anemia treatment market size is expected to see strong growth in the next few years. It will grow to $1.95 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing incidence of AIHA worldwide, rising demand for targeted therapies, growing focus on personalized medicine, increasing investment in autoimmune disease research, and growing healthcare access in developing regions. Major trends in the forecast period include technological advancements in diagnostics, digital health and telemedicine integration, advancements in targeted therapies, AI-powered diagnostics and drug discovery, and novel immunosuppressive strategies.
Claim your free report sample now:
Which Factors Are Driving Growth in the Autoimmune Hemolytic Anemia Treatment Market?
Rising prevalence of autoimmune diseases is expected to propel the growth of the autoimmune hemolytic anemia treatment market going forward. Autoimmune disorders refer to diseases in which the immune system mistakenly attacks the body's own tissues, causing inflammation and damage. The increasing prevalence of autoimmune diseases is largely driven by genetic predisposition, which makes individuals more susceptible to developing these conditions. The treatment of autoimmune hemolytic anemia plays a crucial role in managing the complications of autoimmune diseases by targeting and reducing the destruction of red blood cells caused by the immune system. For instance, May 2023, according to the National Institute for Health and Care Research (NIHR), is a UK-based organization that funds, supports, and delivers health and care research to improve people's health and well-being. A study of 22 million people reveals that autoimmune disorders now impact approximately one in ten individuals, with 19 autoimmune diseases affecting around 10% of the population 13% of women and 7% of men. Therefore, Rising Prevalence Of Autoimmune Diseases will drive the growth of the autoimmune hemolytic anemia treatment market.
What Are the Core Segments Shaping the Autoimmune Hemolytic Anemia Treatment Market Landscape?
The autoimmune hemolytic anemia treatment market covered in this report is segmented –
1) By Type: Warm Autoimmune Hemolytic Anemia, Cold Autoimmune Hemolytic Anemia, Other Types
2) By Drug Class: Corticosteroids, Immunosuppressive Agents, Other Drug Classes
3) By Route Of Administration: Injectable, Oral, Other Route Of Administrations
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Warm Autoimmune Hemolytic Anemia: Primary Warm Autoimmune Hemolytic Anemia, Secondary Warm Autoimmune Hemolytic Anemia
2) By Cold Autoimmune Hemolytic Anemia: Primary Cold Agglutinin Disease (CAD), Secondary Cold Autoimmune Hemolytic Anemia
3) By Other Types: Mixed-Type Autoimmune Hemolytic Anemia, Paroxysmal Cold Hemoglobinuria (PCH), Drug-Induced Autoimmune Hemolytic Anemia
What Are the Top Trends Expected to Shape the Autoimmune Hemolytic Anemia Treatment Market by 2029?
Major companies operating in the autoimmune hemolytic anemia treatment market are focusing on advancements in targeted therapies, such as first-in-class monoclonal antibodies, to precisely inhibit specific immune pathways like the classical complement system and reduce red blood cell destruction with fewer side effects. First-in-class monoclonal antibodies are novel therapeutic antibodies that target unique mechanisms or pathways in the body, which have never been previously targeted by any approved treatments. For instance, In November 2022, Sanofi S.A., a France-based healthcare company, received marketing authorization from the European Commission for Enjaymo (sutimlimab), a monoclonal antibody designed to target and inhibit the C1s protein in the classical complement pathway. This therapy is used to treat hemolytic anemia in adults with Cold Agglutinin Disease (CAD), a rare, chronic autoimmune condition where the immune system mistakenly destroys healthy red blood cells, causing hemolysis. Enjaymo's mechanism helps reduce red blood cell destruction, offering a targeted treatment for CAD, a type of autoimmune hemolytic anemia (AIHA).
Which Are the Top Companies in the Autoimmune Hemolytic Anemia Treatment Market?
Major companies operating in the autoimmune hemolytic anemia treatment market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi SA, Novartis AG, Amgen Inc., Incyte Corporation, Alexion Pharmaceuticals Inc., Hutchison China MediTech Limited, BioCryst Pharmaceuticals Inc., Annexon Inc., Rigel Pharmaceuticals Inc., Nanjing IASO Biotherapeutics Co. Ltd., Apellis Pharmaceuticals Inc., Momenta Pharmaceuticals Inc., Zenas BioPharma Inc., Immunovant Sciences GmbH, Alpine Immune Sciences Inc., Agios Pharmaceuticals Inc., Kezar Life Sciences Inc.
Get the full autoimmune hemolytic anemia treatment market report here:
Which Regions Are Driving the Most Demand in the Autoimmune Hemolytic Anemia Treatment Market?
North America was the largest region in the autoimmune hemolytic anemia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the autoimmune hemolytic anemia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment